Please login to the form below

Not currently logged in
Email:
Password:

GSK benefiting from joint R&D

GlaxoSmithKline and Pozen announced on April 17 that the US Food and Drug Administration has approved the migraine medication Treximet
GlaxoSmithKline (GSK) and Pozen announced on April 17 that the US Food and Drug Administration (FDA) has approved the migraine medication Treximet.

Treximet has been developed to treat migraine and could be available in the US market as early as mid-May 2008. Trials into the drug have shown it to be more effective than sumatriptan and naproxen, two existing migraine medications, both of which are components of Treximet.

More than 3,700 migraine patients have been involved in extensive clinical trials that saw Treximet used to treat almost 30,000 migraine attacks.

Dr Stephen Silberstein, professor of neurology and director of the Jefferson Headache Centre at Thomas Jefferson University, said: "The FDA approval of Treximet is good news for migraine patients because clinical trials showed that Treximet produced sustained migraine pain relief for a significant number of patients."

"Migraine patients want their medicine to work early and to continue to provide relief," he added.

GSK has also announced an alliance with Regulus Therapeutics to launch an R&D programme to discover novel microRNA-targeted therapeutics for treating inflammatory conditions, such as rheumatoid arthritis and bowel disease. Regulus will be given a $20m upfront payment as part of the deal.

17th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics